Somewhat Positive Press Coverage Somewhat Unlikely to Affect Ra Pharmaceuticals (RARX) Share Price

News headlines about Ra Pharmaceuticals (NASDAQ:RARX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.4056927366894 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Ra Pharmaceuticals (RARX) opened at $14.23 on Monday. Ra Pharmaceuticals has a 52 week low of $11.20 and a 52 week high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). research analysts predict that Ra Pharmaceuticals will post -2.46 EPS for the current fiscal year.

A number of brokerages recently issued reports on RARX. Zacks Investment Research upgraded Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Credit Suisse Group raised their target price on Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Royal Bank Of Canada began coverage on Ra Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Jefferies Group restated a “buy” rating and issued a $25.00 target price on shares of Ra Pharmaceuticals in a research note on Thursday, September 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $23.20.

TRADEMARK VIOLATION WARNING: This news story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/04/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-ra-pharmaceuticals-rarx-share-price.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

What are top analysts saying about Ra Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ra Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit